InMed Pharmaceuticals
7 hedge funds and large institutions have $28.5K invested in InMed Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
115% more capital invested
Capital invested by funds: $13.3K → $28.5K (+$15.2K)
40% more funds holding
Funds holding: 5 → 7 (+2)
0.17% more ownership
Funds ownership: 0.53% → 0.7% (+0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$4.59K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.11K |
| 3 |
Bessemer Group
Woodbridge,
New Jersey
|
+$3 |
Top Sellers
INM Hedge Fund Activity: Q2 2025 in Review
7 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q2 2025, worth a combined $28.5K — up 115% from $13.3K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new INM positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $4.59K.
- 7 institutional investors held InMed Pharmaceuticals (INM) as of Q2 2025, up from 5 in Q1 2025.
- Funds reported $28.5K of InMed Pharmaceuticals stock for Q2 2025, up 115% quarter-over-quarter.
- 2 funds opened new InMed Pharmaceuticals positions in Q2 2025 and 0 closed out, a net change of +2 holders.
- The largest InMed Pharmaceuticals buyer in Q2 2025 was UBS Group, an estimated $4.59K added.
Based on aggregated 13F filings for Q2 2025.